5 completed, 1 active not recruiting, 1 terminated. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Active not recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow Shingles: new trials by email Literature Review of Shingles trials Research Report on Shingles
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over Z-1018, Shingrix - Shingles, Herpes Zoster | Phase 1 / Phase 2 | Active not recruiting | Dynavax Technologies Corporation | 764 | 2024-06-17 | 2026-10-16 |
| A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine JCXH-105, Active Control (Shingrix) - Herpes Zoster (HZ), Shingles | Phase 1 | Completed | Immorna Biotherapeutics, Inc. | 75 | 2023-05-26 | 2024-09-19 |
| A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection - Shingles, Herpes Zoster Infection | Phase 1 / Phase 2 | Terminated | Pfizer | 484 | 2023-01-25 | 2026-05-04 |
| Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers Z-1018, Shingrix - Shingles, Herpes Zoster | Phase 1 | Completed | Dynavax Technologies Corporation | 150 | 2022-01-10 | 2022-11-07 |
| Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds Zostavax, HZ/su vaccine, Placebo - Shingles, Herpes Zoster | Phase 1 | Completed | University of Colorado, Denver | 160 | 2014-05-01 | 2020-07-08 |
| Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents Varicella Zoster Virus Vaccine (Zostavax) - Immunosenescence, Shingles | Phase 1 | Completed | University of Colorado, Denver | 33 | 2010-11-01 | 2021-06-25 |
| Valacyclovir in Immunocompromised Children Valacyclovir - Shingles, Bone Marrow Transplantation | Phase 1 | Completed | Baylor College of Medicine | 37 | 1998-04-07 | 2020-03-04 |
Herpes Zoster (7) · Chickenpox (2) · Vaccine-Preventable Diseases (2) · Communicable Diseases (1)
DNA Virus Infections (7) · Herpesviridae Infections (7) · Infections (7) · Varicella Zoster Virus Infection (7) · Virus Diseases (7) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Herpes Zoster Vaccine (2) · Injections (1) · Saline Solution (1) · Suspensions (1) · Vaccines, Synthetic (1) · Valacyclovir (1)
Dynavax Technologies Corporation (2) · University of Colorado, Denver (2) · Baylor College of Medicine (1) · Immorna Biotherapeutics, Inc. (1) · Pfizer (1)
United States (5) · Australia (2) · New Zealand (1)
Adit A Ginde, MD, MPH (1) · Myron J Levin, M.D. (1) · Susan Blaney, MD (1)
PMID 30247596, PMID 34850039, PMID 37781954
K23AG040708 (1)